Galmed Pharmaceuticals

Galmed Pharmaceuticals Ltd. is a clinical-stage biopharmaceutical company based in Tel Aviv-Yafo, Israel, specializing in the development of therapeutics for liver diseases and metabolic disorders. The company's lead product, Aramchol, is an oral therapy designed to treat non-alcoholic steatohepatitis (NASH) and is currently undergoing a Phase III pivotal study. Aramchol is recognized for its potential to modify disease progression and improve metabolic parameters in patients with liver fat disorders. Additionally, Galmed is conducting the ARRIVE Study, a Phase IIa trial exploring Aramchol's efficacy in patients with HIV-associated non-alcoholic fatty liver disease and lipodystrophy. The company has formed strategic collaborations to enhance its research efforts, including a partnership with Gannex Pharma Co., Ltd. to develop a combination therapy for NASH and with MyBiotics Pharma Ltd. to investigate microbiome responses to Aramchol. Founded in 2000, Galmed Pharmaceuticals is committed to addressing significant unmet medical needs in liver health.